[go: up one dir, main page]

AU2001287977A1 - Controlled release formulations for oral administration - Google Patents

Controlled release formulations for oral administration

Info

Publication number
AU2001287977A1
AU2001287977A1 AU2001287977A AU8797701A AU2001287977A1 AU 2001287977 A1 AU2001287977 A1 AU 2001287977A1 AU 2001287977 A AU2001287977 A AU 2001287977A AU 8797701 A AU8797701 A AU 8797701A AU 2001287977 A1 AU2001287977 A1 AU 2001287977A1
Authority
AU
Australia
Prior art keywords
oral administration
controlled release
release formulations
formulations
controlled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001287977A
Inventor
Gour Mukherji
Rajeev S. Raghuvanshi
Ashok Rampal
Narayanan Badri Vishwanathan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IN856DE2000 external-priority patent/IN192864B/en
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of AU2001287977A1 publication Critical patent/AU2001287977A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001287977A 2000-09-22 2001-09-22 Controlled release formulations for oral administration Abandoned AU2001287977A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN856/DEL/2000 2000-09-22
IN856DE2000 IN192864B (en) 2000-09-22 2000-09-22
IN881DE2001 2001-08-24
IN881/DEL/2001 2001-08-24
PCT/IB2001/001743 WO2002024203A2 (en) 2000-09-22 2001-09-22 Controlled release formulations for oral administration

Publications (1)

Publication Number Publication Date
AU2001287977A1 true AU2001287977A1 (en) 2002-04-02

Family

ID=26324883

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001287977A Abandoned AU2001287977A1 (en) 2000-09-22 2001-09-22 Controlled release formulations for oral administration

Country Status (9)

Country Link
US (1) US20020119192A1 (en)
EP (1) EP1322313A2 (en)
KR (1) KR20030048410A (en)
CN (1) CN1471398A (en)
AP (1) AP2003002763A0 (en)
AU (1) AU2001287977A1 (en)
BR (1) BR0114100A (en)
MX (1) MXPA03002569A (en)
WO (1) WO2002024203A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0313207A (en) * 2002-08-02 2005-06-28 Ranbaxy Lab Ltd Storage-stable fosinopril sodium tablets, process for preparing them and method for treating hypertension
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
WO2004096182A1 (en) * 2003-04-30 2004-11-11 Ranbaxy Laboratories Limited Extended release matrix tablets of carvedilol
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
JP4931596B2 (en) 2003-11-07 2012-05-16 ユーエス スモークレス タバコ カンパニー リミテッド ライアビリティ カンパニー Tobacco composition
PL1729739T3 (en) 2004-03-29 2017-04-28 Les Laboratoires Servier Process for preparing a solid pharmaceutical composition
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US20050260263A1 (en) * 2004-05-18 2005-11-24 Panion & Bf Biotech Inc. Sustained release formulation for sparingly soluble main drugs
US20060045911A1 (en) * 2004-08-27 2006-03-02 Sun Pharmaceutical Industries Ltd. Stable pharmaceutical formulations
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
AU2007355452B2 (en) * 2007-06-25 2011-12-15 Pharmathen S.A. Improved pharmaceutical formulation containing an HMG-CoA reductase inhibitor and method for the preparation thereof
US20120027855A1 (en) * 2007-07-06 2012-02-02 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
WO2010019915A1 (en) * 2008-08-15 2010-02-18 Depomed Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders
AU2009301994B2 (en) * 2008-10-08 2016-10-20 Bioplus Life Sciences Pvt. Ltd. Sustained release drug delivery system
WO2010106555A2 (en) * 2009-03-17 2010-09-23 Shantilal, Doshi, Bimalkumar Directly compressible pre-granulated cellulose ether polymer and process for preparing the same
US20110200671A1 (en) * 2010-02-17 2011-08-18 Sun Pharma Advanced Research Company Ltd. Method of treating a disease condition susceptible to baclofen therapy
EP2882494A1 (en) 2012-08-07 2015-06-17 Topgenix Inc. Topical composition comprising transformed bacteria expressing a compound of interest
CN107106501B (en) * 2014-12-23 2021-07-06 杜邦营养美国有限公司 Enteric film coating composition, coating method and coated formulation
US11324774B2 (en) * 2018-01-05 2022-05-10 Augusta University Research Institute, Inc. Compositions of oral alkaline salts and metabolic acid inducers and uses thereof
CN110840866A (en) * 2018-08-20 2020-02-28 成都新睿泰康科技有限公司 Asarin pharmaceutical composition and application thereof in preventing and treating neurodegenerative diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0200508B1 (en) * 1985-04-27 1991-10-02 Nitto Denko Corporation Adhesive oral bandages and oral pharmaceutical preparations
US5686094A (en) * 1991-04-01 1997-11-11 Theratech, Inc. Controlled release formulations for the treatment of xerostomia
ATE170745T1 (en) * 1991-04-08 1998-09-15 Nippon Shinyaku Co Ltd CAPSULE WITH LONG-TERM EFFECT FOR ADHESION IN THE GASTROINTESTINAL TRACT
AU2367900A (en) * 1998-12-18 2000-07-03 Bayer Corporation Chewable drug delivery system
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

Also Published As

Publication number Publication date
CN1471398A (en) 2004-01-28
MXPA03002569A (en) 2003-10-14
WO2002024203A2 (en) 2002-03-28
AP2003002763A0 (en) 2003-03-31
KR20030048410A (en) 2003-06-19
EP1322313A2 (en) 2003-07-02
BR0114100A (en) 2003-10-21
US20020119192A1 (en) 2002-08-29
WO2002024203A3 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
AU2002258563A1 (en) Pharmaceutical formulations for sustained release
AU6089200A (en) Rapid immediate release oral dosage form
AU2002229140A1 (en) Controlled release pharmaceutical composition
AU3977099A (en) Controlled release oral dosage form
AU2276801A (en) Extended release oral dosage composition
AU2277101A (en) Stable extended release oral dosage composition
AU2001287977A1 (en) Controlled release formulations for oral administration
IL155293A0 (en) Delayed release pharmaceutical formulations
AU2001248769A1 (en) Time-release coated solid compositions for oral administration
AU2002239397A1 (en) Drug formulation having improved oral tolerability
AU2003213151A1 (en) Controlled release solid dosage carbamazepine formulations
AU2001280908A1 (en) Rotavirus vaccine formulations
AU2001284444A1 (en) Preparations for oral administration
HUP0301177A3 (en) Ion-strength independent sustained release pharmaceutical formulation
AU2002214324A1 (en) Medicinal compositions
EP1207852A4 (en) Controlled release oral dosage suitable for oral administration
AU2001290239A1 (en) Medicinal composition
AU2001272314A1 (en) Oral formulations for localized colonic release and the method of preparation thereof
AU2001256201A1 (en) Device for administering implants
AU6715600A (en) Pharmaceutical formulations
AU1304601A (en) Solid preparations for oral use
AU2001248336A1 (en) Controlled release oral solid forms containing mesalazine as active agent
AU2564399A (en) Isoflavanoid formulations for oral administration
AU2001248772A1 (en) Sustained release drug compositions
IL148908A0 (en) Oral controlled release formulations